Share This Author
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
The ESSDAI is a clinical index designed to measure disease activity in patients with primary Sjögren's syndrome and should facilitate clinical research and be helpful as an outcome measure in clinical trials.
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
The EULAR SS Patient Reported Index is a very simple index designed to measure patients' symptoms in primary SS and has good construct validity and is well correlated with SSI and PROFAD.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Considering the limitations of an open-label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active RA treated in clinical practice.
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
A user guide for the ESSDAI is provided, which provides definitions and precisions on the rating of each domain, and includes some minor improvement of the score to integrate advance in knowledge of disease manifestations.
Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome
Patients with systemic extraepithelial manifestations display low serum levels of the complement component C4 and mixed type II cryoglobulins, and show an increased risk of developing non-Hodgkin lymphoma, thereby reflecting an overall worse prognosis with higher mortality rates than those without extraepIThelial manifestations.
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome.
- A. Tzioufas, D. Boumba, F. Skopouli, H. Moutsopoulos
- Medicine, BiologyArthritis and rheumatism
- 1 May 1996
The determination of MMC can be used as a laboratory predictive factor for lymphoma development in primary SS and CRIs 17109 and G-6 may also be used to predict lymph cancer development, especially when the monoclonal component is absent.
Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells.
Knowledge of SjS has progressed substantially, but this disease is still characterized by sicca symptoms, the systemic involvement of disease, lymphocytic infiltration to exocrine glands, the presence of anti-Ro/SSA and anti-La/SSB autoantibodies and the increased risk of lymphoma in patients with SJS.
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.
Anti-P antibody testing has limited diagnostic value for NPSLE, and it is not helpful in differentiating among various disease phenotypes.